SCHEMBL5136743

SCHEMBL5136743

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(CC)Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.45
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CNR2 P34972 1/20 0.40
ICMT O60725 1/20 0.40
TSHR P16473 2/20 0.39
CRHR1 P34998 3/20 0.39
TRPV4 Q9HBA0 1/20 0.39
ADORA2B P29275 2/20 0.38
TLR8 Q9NR97 1/20 0.38
P2RX3 P56373 1/20 0.38
ADORA3 P0DMS8 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
UBE2M P61081 2/20 0.37
DCUN1D1 Q96GG9 2/20 0.37
DHFR P00374 1/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650105 0.95 C5AR1 (0.46) C5AR1MEN1KMT2ATSHRCRHR1
SCHEMBL649523 0.93 MEN1 (0.46) C5AR1MEN1KMT2ACNR2TSHR
SCHEMBL5137122 0.93 MEN1 (0.46) C5AR1MEN1KMT2ACNR2TSHR
SCHEMBL648166 0.91 C5AR1 (0.43) C5AR1MEN1KMT2ATSHRCRHR1
SCHEMBL651220 0.89 C5AR1 (0.41) C5AR1MEN1KMT2AICMTTRPV4
SCHEMBL5134817 0.89 CRHR1 (0.43) C5AR1MEN1KMT2ACRHR1TRPV4
SCHEMBL649941 0.89 C5AR1 (0.41) C5AR1MEN1KMT2ATSHRCRHR1
SCHEMBL5136656 0.88 C5AR1 (0.46) C5AR1MEN1KMT2ACNR2ICMT
SCHEMBL5135739 0.88 C5AR1 (0.48) C5AR1MEN1KMT2ATSHRCRHR1
SCHEMBL5137883 0.88 TSHR (0.48) C5AR1TSHRKDM4EALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed